J. Badimón

V. Fuster, J. Badimón, A. Gass, 1999, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

Local inhibition of tissue factor reduces the thrombogenicity of disrupted human atherosclerotic plaques: effects of tissue factor pathway inhibitor on plaque thrombogenicity under flow conditions.

V. Fuster, V. Fuster, J. Badimón, 1999, Circulation.

Acute biological response to laser balloon angioplasty in the atherosclerotic rabbit

V. Fuster, J. Badimón, J. Marmur, 1994, Lasers in surgery and medicine.

Role of von Willebrand factor in mediating platelet-vessel wall interaction at low shear rate; the importance of perfusion conditions

V. Fuster, J. Badimón, L. Badimón, 1989 .

Prolyl Hydroxylase Inhibitors: a New Opportunity in Renal and Myocardial Protection

J. Badimón, M. U. Zafar, J. A. Requena-Ibáñez, 2021, Cardiovascular Drugs and Therapy.

Synergistic effect of liver X receptor activation and simvastatin on plaque regression and stabilization: an magnetic resonance imaging study in a model of advanced atherosclerosis.

V. Fuster, J. Badimón, C. Giannarelli, 2012, European heart journal.

New Understanding of Atherosclerosis (Clinically and Experimentally) with Evolving MRI Technology in Vivo

V. Fuster, Z. Fayad, J. Badimón, 2001, Annals of the New York Academy of Sciences.

Evolving Concepts in the Triad of Atherosclerosis, Inflammation and Thrombosis

V. Fuster, J. Badimón, R. Corti, 2004, Journal of Thrombosis and Thrombolysis.

Pathogenetic concepts of acute coronary syndromes.

V. Fuster, J. Badimón, R. Corti, 2003, Journal of the American College of Cardiology.

Artery dissection and arterial thrombus aging: the role of noninvasive magnetic resonance imaging.

V. Fuster, Z. Fayad, J. Badimón, 2001, Circulation.

Effects of platelet glycoprotein IIb/IIIa inhibition with abciximab on thrombin generation and activity during percutaneous coronary intervention.

G. Dangas, J. Badimón, J. Marmur, 1999, American heart journal.

Lethal myocardial reperfusion injury: a necessary evil?

V. Fuster, J. Badimón, B. Ibáñez, 2011, International journal of cardiology.

Long-term secondary prevention of cardiovascular disease with a Mediterranean diet and a low-fat diet (CORDIOPREV): a randomised controlled trial

J. M. Fernández, F. Rodríguez‐Artalejo, J. Badimón, 2022, The Lancet.

Duration of antiplatelet therapy after complex PCI in the TWILIGHT-COMPLEX trial: the Goldilocks dilemma.

J. Badimón, C. Santos-Gallego, 2020, Cardiovascular research.

The role of the new oral anticoagulants in the treatment of coronary disease

J. Badimón, H. Portillo, Jaime Cabrales, 2016 .

Reperfusion-triggered stress protein response in the myocardium is blocked by post-conditioning. Systems biology pathway analysis highlights the key role of the canonical aryl-hydrocarbon receptor pathway.

J. Badimón, G. Vilahur, L. Badimón, 2013, European heart journal.

The cardioprotection granted by metoprolol is restricted to its administration prior to coronary reperfusion.

Mario J. Garcia, V. Fuster, J. Badimón, 2011, International journal of cardiology.

Are the antidiabetic SGLT2 inhibitors a cardiovascular treatment?

J. Badimón, C. Santos-Gallego, Ariana P. Vargas Delgado, 2020, Clinica e investigacion en arteriosclerosis : publicacion oficial de la Sociedad Espanola de Arteriosclerosis.

Correlation between myocardial strain and adverse remodeling in a non-diabetic model of heart failure following empagliflozin therapy

J. Badimón, K. Ishikawa, C. Santos-Gallego, 2020, Expert review of cardiovascular therapy.

Metabolism of the failing heart and the impact of SGLT2 inhibitors

J. Badimón, M. U. Zafar, C. Santos-Gallego, 2019, Expert opinion on drug metabolism & toxicology.

SGLT Receptors and Myocardial Ischemia-Reperfusion Injury: Inhibition of SGLT-1, SGLT-2 or both?

J. Badimón, C. Santos-Gallego, Á. García-Ropero, 2019, Cardiovascular research.

Inhibition of Sodium Glucose Cotransporters Improves Cardiac Performance

J. Badimón, C. Santos-Gallego, Á. García-Ropero, 2019, International journal of molecular sciences.

Idarucizumab, but not procoagulant concentrates, fully restores dabigatran‐altered platelet and fibrin components of hemostasis

J. Badimón, I. López-Vílchez, M. Díaz-Ricart, 2019, Transfusion.

Shear stress-dependent platelet function after LDL cholesterol apheresis.

F. Ruschitzka, J. Badimón, G. Noll, 2004, Thrombosis research.

Testing Platelet Activation With a Shear-Dependent Platelet Function Test Versus Aggregation-Based Tests: Relevance for Monitoring Long-Term Glycoprotein IIb/IIIa Inhibition

V. Fuster, J. Badimón, D. Shimbo, 2001, Circulation.

Estimation of the major cardiovascular events prevention with Inclisiran.

J. Badimón, J. Núñez, J. González-Juanatey, 2020, Atherosclerosis.

Adeno-associated Virus Serotype 8 ApoA-I Gene Transfer Reduces Progression of Atherosclerosis in ApoE-KO Mice: Comparison of Intramuscular and Intravenous Administration

V. Fuster, J. Badimón, C. Giannarelli, 2011, Journal of cardiovascular pharmacology.

Cardiovascular implications of HIV-induced dyslipidemia.

J. Badimón, C. Giannarelli, R. Klein, 2011, Atherosclerosis.

Platelet-inhibitor drugs' role in coronary artery disease.

V. Fuster, J. Badimón, J. Chesebro, 1987, Progress in cardiovascular diseases.

Effect of High-Density Lipoproteins on Experimental Atherosclerosis

V. Fuster, J. Badimón, L. Badimón, 1987 .

Changes of plasma levels of apolipoproteins A-I, A-II, and B and their isoforms in patients with intestinal failure receiving long-term parenteral nutrition.

J. Badimón, S. Mao, C. Fleming, 1987, The American journal of clinical nutrition.

Monoclonal antibodies to human plasma low-density lipoproteins. II. Evaluation for use in radioimmunoassay for apolipoprotein B in patients with coronary artery disease.

J. Badimón, S. Mao, J. Patton, 1983, Clinical chemistry.

Thrombolysis and Adjunctive Therapies in Acute Myocardial Infarction

J. Badimón, A. Zaman, G. Helft, 2000, Pathophysiology of Haemostasis and Thrombosis.

Pathogenesis of thrombosis in coronary artery disease.

V. Fuster, J. Badimón, J. Chesebro, 1997, Haemostasis.

Thrombin in arterial thrombosis.

J. Badimón, L. Badimón, B. Meyer, 1994, Haemostasis.

Prolonged Thrombin Inhibition Reduces Restenosis After Balloon Angioplasty in Porcine Coronary Arteries

V. Fuster, J. Badimón, J. Fallon, 1996 .

Antiplatelet agents: Is twice a day a better strategy?

J. Badimón, H. C. Arazi, 2017 .

Carvedilol administration in acute myocardial infarction results in stronger inhibition of early markers of left ventricular remodeling than metoprolol.

Mario J. Garcia, V. Fuster, J. Badimón, 2011, International journal of cardiology.

Platelet function normalization after a prasugrel loading‐dose: time‐dependent effect of platelet supplementation

V. Fuster, J. Badimón, C. Giannarelli, 2013, Journal of thrombosis and haemostasis : JTH.

Impact of Timing on the Functional Recovery Achieved With Platelet Supplementation After Treatment With Ticagrelor

V. Fuster, J. Badimón, U. Baber, 2017, Circulation. Cardiovascular interventions.

Per‐Protocol Versus Intention‐to‐Treat in Clinical Trials: The Example of GLOBAL‐LEADERS Trial

J. Badimón, J. A. Requena-Ibáñez, C. Santos-Gallego, 2022, Journal of the American Heart Association.

Ticagrelor With or Without Aspirin After PCI: The TWILIGHT Platelet Substudy.

Samin K. Sharma, V. Fuster, G. Dangas, 2020, Journal of the American College of Cardiology.

Combined and independent impact of diabetes mellitus and chronic kidney disease on residual platelet reactivity

Samin K. Sharma, J. Badimón, R. Mehran, 2013, Thrombosis and Haemostasis.

Atherothrombosis: role of tissue factor; link between diabetes, obesity and inflammation.

J. Badimón, P. Moreno, G. Cimmino, 2007, Indian journal of experimental biology.

Pathophysiological role of blood-borne tissue factor: should the old paradigm be revisited?

J. Badimón, G. Cimmino, P. Golino, 2011, Internal and emergency medicine.

Is the Endothelium the Missing Link in the Pathophysiology and Treatment of COVID-19 Complications?

P. Richardson, J. Badimón, M. Díaz-Ricart, 2021, Cardiovascular Drugs and Therapy.

Rapid Change in Plaque Size, Composition, and Molecular Footprint After Recombinant Apolipoprotein A-IMilano (ETC-216) Administration

V. Fuster, J. Badimón, B. Ibáñez, 2008 .

, Claudia and VEGF Signaling α HIF-1 Alternatively Spliced Tissue Factor Promotes Plaque Angiogenesis Through the Activation of

V. Fuster, Z. Fayad, P. Faries, 2014 .

Effects of aggressive versus conventional lipid-lowering therapy by simvastatin on human atherosclerotic lesions: a prospective, randomized, double-blind trial with high-resolution magnetic resonance imaging.

V. Fuster, W. Chaplin, Z. Fayad, 2005, Journal of the American College of Cardiology.

Atherosclerosis regression and TP receptor inhibition: effect of S18886 on plaque size and composition--a magnetic resonance imaging study.

V. Fuster, J. Badimón, Carolina Valdiviezo, 2005, European heart journal.

Effect of Percutaneous Transluminal Angioplasty on Severely Stenotic Femoral Lesions In Vivo Demonstration by Noninvasive Magnetic Resonance Imaging

V. Fuster, J. Badimón, A. Gallino, 2002 .

Strategy for ensuring a better future for the vessel wall

V. Fuster, J. Badimón, R. Corti, 2002 .

Administration of eptifibatide to acute coronary syndrome patients receiving enoxaparin or unfractionated heparin: effect on platelet function and thrombus formation.

A. Tobar, J. Badimón, R. Kornowski, 2004, Journal of the American College of Cardiology.

Statins and Plaque Stability

V. Fuster, Z. Fayad, J. Badimón, 2003, Journal of cardiovascular risk.

Dual antiplatelet therapy and drug eluting stents: a marriage of convenience

J. Badimón, B. Ibáñez, J. Benezet-Mazuecos, 2007, Thrombosis journal.

Viewpoint Overcoming restenosis with sirolimus: from alphabet soup to clinical reality

V. Fuster, J. Badimón, M. Poon, 2002, The Lancet.

Escitalopram Impairs Thrombin-Induced Platelet Response, Cytoskeletal Assembly and Activation of Associated Signalling Pathways

J. Badimón, I. López-Vílchez, M. Díaz-Ricart, 2017, Thrombosis and Haemostasis.

Intravascular Drug Delivery

V. Fuster, E. Falk, J. Badimón, 2005 .

Baseline platelet activity and response after clopidogrel in 257 diabetics among 822 patients with coronary artery disease

J. Badimón, J. Chesebro, V. Serebruany, 2008, Thrombosis and Haemostasis.

Sphingosine-1-Phosphate Receptor Agonist Fingolimod Increases Myocardial Salvage and Decreases Adverse Postinfarction Left Ventricular Remodeling in a Porcine Model of Ischemia/Reperfusion

V. Fuster, P. Sengupta, J. Badimón, 2016, Circulation.

Early Benefits of Pravastatin to Experimentally Induced Atherosclerosis

J. Badimón, F. Fonseca, S. Ihara, 2002, Journal of cardiovascular pharmacology.

Tissue Factor Coagulation Pathway: A New Therapeutic Target in Atherothrombosis

V. Fuster, J. Badimón, M. U. Zafar, 2004, Journal of cardiovascular pharmacology.

Cardiac gated breath-hold black blood MRI of the coronary artery wall: An in vivo and ex vivo comparison

V. Fuster, Z. Fayad, J. Badimón, 2001, The International Journal of Cardiovascular Imaging.

Therapeutic Potential of Ketone Bodies for Patients With Cardiovascular Disease: JACC Focus Seminar.

R. D. de Boer, J. Badimón, D. Kelly, 2021, Journal of the American College of Cardiology.

The complement component C5a is present in human coronary lesions in vivo and induces the expression of MMP‐1 and MMP‐9 in human macrophages in vitro

J. Badimón, G. Maurer, K. Huber, 2011, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

Platelet reactivity and nonresponse to dual antiplatelet therapy: A review

J. Badimón, M. U. Zafar, P. Vila, 2009, Platelets.

A pharmacodynamic comparison of prasugrel vs. high-dose clopidogrel in patients with type 2 diabetes mellitus and coronary artery disease: results of the Optimizing anti-Platelet Therapy In diabetes MellitUS (OPTIMUS)-3 Trial

J. Badimón, M. Effron, B. Baker, 2011, European heart journal.

A new oral antiplatelet agent with potent antithrombotic properties: Comparison of DZ-697b with clopidogrel in a randomised phase I study

J. Badimón, B. Ibáñez, M. U. Zafar, 2009, Thrombosis and Haemostasis.

CCR2 Deficiency Decreases Intimal Hyperplasia After Arterial Injury

J. Badimón, J. Fallon, M. Roqué, 2002, Arteriosclerosis, thrombosis, and vascular biology.

Clinical and Experimental Experience with Factor Xa Inhibitors

V. Fuster, J. Badimón, J. Viles‐Gonzalez, 2004, American journal of cardiovascular drugs : drugs, devices, and other interventions.

Antithrombotic Effects of DX-9065a, a Direct Factor Xa Inhibitor

V. Fuster, J. Badimón, D. Shimbo, 2002, Thrombosis and Haemostasis.

Antithrombotic effects of factor Xa inhibition with DU-176b: Phase-I study of an oral, direct factor Xa inhibitor using an ex-vivo flow chamber

V. Fuster, J. Badimón, P. Moreno, 2007, Thrombosis and Haemostasis.

Atherosclerosis and the vulnerable plaque--pathogenesis: Part I.

V. Fuster, J. Badimón, A. Zaman, 2000, Australian and New Zealand journal of medicine.

Internalization of microparticles by platelets is partially mediated by toll-like receptor 4 and enhances platelet thrombogenicity.

J. Badimón, I. López-Vílchez, M. Díaz-Ricart, 2019, Atherosclerosis.

Recombinant HDL(Milano) exerts greater anti-inflammatory and plaque stabilizing properties than HDL(wild-type).

V. Fuster, J. Badimón, C. Giannarelli, 2012, Atherosclerosis.

Prostanoid and TP-receptors in atherothrombosis: Is there a role for their antagonism?

J. Badimón, C. Giannarelli, M. U. Zafar, 2010, Thrombosis and Haemostasis.

Differential inhibitory action of apixaban on platelet and fibrin components of forming thrombi: Studies with circulating blood and in a platelet-based model of thrombin generation

J. Badimón, I. López-Vílchez, M. Díaz-Ricart, 2017, PloS one.

Comparison of platelet function and morphology in patients undergoing percutaneous coronary intervention receiving bivalirudin versus unfractionated heparin versus clopidogrel pretreatment and bivalirudin.

Samin K. Sharma, J. Badimón, A. Kini, 2007, The American journal of cardiology.

Decreased Reendothelialization and Increased Neointima Formation With Endostatin Overexpression in a Mouse Model of Arterial Injury

V. Fuster, J. Badimón, J. Fallon, 2003, Circulation.

Acute myocardial infarction and the role of aspirin, heparin, and Warfarin

J. Badimón, J. Chesebro, R. McBane, 2005, Journal of Thrombosis and Thrombolysis.

Platelet glycoprotein IIb/IIIa receptor blockade in unstable coronary disease.

J. Badimón, J. Chesebro, 1998, The New England journal of medicine.

Thrombosis on atherosclerotic lesions: Implications for therapy

V. Fuster, J. Badimón, A. Fernández-Ortiz, 1994 .

An acute surge of epinephrine stimulates platelet deposition to severely damaged vascular wall

V. Fuster, J. Badimón, L. Badimón, 1990 .

Baseline Characteristics and Clinical Management of Patients Attended in Primary Care Setting According to the Presence of Cardiovascular Disease

J. Badimón, C. Escobar, J. Llisterri, 2017 .

Dehydroepiandrosterone Feeding Prevents Aortic Fatty Streak Formation and Cholesterol Accumulation in Cholesterol‐fed Rabbit

Y. Arad, J. Badimón, H. Ginsberg, 1989, Arteriosclerosis.

Antithrombotic Effect of Tissue Factor Inhibition by Inactivated Factor VIIa: An Ex Vivo Human Study

J. Badimón, A. Lincoff, E. Lev, 2002, Arteriosclerosis, thrombosis, and vascular biology.

Atherothrombosis: the role of tissue factor.

J. Badimón, J. Viles‐Gonzalez, 2004, The international journal of biochemistry & cell biology.

Mechanism of arterial thrombosis platelet thrombus deposition in areas of stenosis

V. Fuster, J. Badimón, L. Badimón, 1987 .

Antithrombotic effects of S 18886, a novel orally active thromboxane A2 receptor antagonist

V. Fuster, J. Badimón, D. Shimbo, 2004, Journal of thrombosis and haemostasis : JTH.

Ticagrelor reduces thrombus formation more than clopidogrel, even when co-administered with bivalirudin.

J. Badimón, R. Mehran, U. Baber, 2014, Thrombosis and haemostasis.

Differences in thrombus structure and kinetics in patients with type 2 diabetes mellitus after non ST elevation acute coronary syndrome

J. Badimón, A. Zaman, S. Marshall, 2014, Thrombosis research.

Antithrombotic therapy and progression of coronary artery disease. Antiplatelet versus antithrombins.

J. Badimón, L. Badimón, P. Roche, 1992, Circulation.

Hypercholesterolemia induces abnormal coronary vasomotion in vivo

V. Fuster, J. Badimón, J. Chesebro, 1991 .

The pathophysiology of thrombosis

J. Badimón, L. Badimón, 2005 .

Electrical Aggregometry in Whole Blood from Human, Pig and Rabbit

V. Fuster, J. Badimón, L. Badimón, 1986, Thrombosis and Haemostasis.

Targeting thrombogenicity and inflammation in chronic HIV infection

J. Badimón, G. Escolar, J. Aberg, 2019, Science Advances.

Incremental effects of diabetes mellitus and chronic kidney disease in medial arterial calcification: Synergistic pathways for peripheral artery disease progression

Samin K. Sharma, J. Badimón, J. Narula, 2019, Vascular medicine.

Spontaneous and Diet‐Induced Coronary Atherosclerosis in Normal Swine and Swine with von Wiiiebrand Disease

V. Fuster, J. Badimón, J. Lie, 1985, Arteriosclerosis.

Regression or stabilization of atherosclerosis means regression or stabilization of what we don't see in the arteriogram.

V. Fuster, J. Badimón, 1995, European heart journal.

Dendritic cells in neointima formation after rat carotid balloon injury: coordinated expression withanti-apoptotic Bcl-2 and HSP47 in arterial repair.

V. Fuster, B. Lüderitz, J. Badimón, 2003, Journal of the American College of Cardiology.

SGLT2-Inhibitors on HFpEF Patients. Role of Ejection Fraction

J. Badimón, M. U. Zafar, J. A. Requena-Ibáñez, 2022, Cardiovascular Drugs and Therapy.

Mechanistic Insights of Empagliflozin in Nondiabetic Patients With HFrEF: From the EMPA-TROPISM Study.

V. Fuster, J. Badimón, D. Mancini, 2021, JACC. Heart failure.

Metabolic syndrome and diabetic atherothrombosis: implications in vascular complications.

V. Fuster, J. Badimón, P. Moreno, 2006, Current molecular medicine.

EMPAGLIFLOZIN INDUCES A MYOCARDIAL METABOLIC SHIFT FROM GLUCOSE CONSUMPTION TO KETONE METABOLISM THAT MITIGATES ADVERSE CARDIAC REMODELING AND IMPROVES MYOCARDIAL CONTRACTILITY

V. Fuster, J. Badimón, R. Hajjar, 2018 .

In vivo demonstration of an antithrombin effect of abciximab.

G. Dangas, J. Badimón, J. Ambrose, 2000, The American journal of cardiology.

Antithrombotic potency of ticagrelor versus clopidogrel in type-2 diabetic patients with cardiovascular disease

V. Fuster, J. Badimón, R. Mehran, 2017, Thrombosis and Haemostasis.

Risk factors: Ethnicity and cardiovascular risk—are all men created equal?

J. Badimón, C. Santos-Gallego, 2012, Nature Reviews Cardiology.

Pathobiology of coronary ischemic events: clinical implications.

V. Fuster, J. Badimón, R. Gallo, 1998, Advances in internal medicine.

Monoclonal antibodies to human plasma low-density lipoproteins. I. Enhanced binding of 125I-labeled low-density lipoproteins by combined use of two monoclonal antibodies.

J. Badimón, M. Alley, S. Mao, 1983, Clinical chemistry.

Statin Therapy Alone and in Combination with an Acyl-CoA:Cholesterol O-Acyltransferase Inhibitor on Experimental Atherosclerosis

V. Fuster, Z. Fayad, J. Badimón, 2008, Pathophysiology of Haemostasis and Thrombosis.

HDL Dysfunction: Is the Answer in the Sphinx's Riddle?

J. Badimón, C. Santos-Gallego, 2015, Journal of the American College of Cardiology.

HDL Dysfunction

J. Badimón, C. Santos-Gallego, Carlos G Santos-Gallego, 2015 .

Reply: empagliflozin effects on cardiac remodeling: re-shaping the future of heart failure prevention

J. Badimón, C. Santos-Gallego, Á. García-Ropero, 2020, Expert review of cardiovascular therapy.

Quantification and immunolocalization of apolipoprotein E in experimental atherosclerosis.

J. Badimón, T. Chen, S. Mao, 1986, Atherosclerosis.

The Association of Antiplatelet Aggregation Effect of Aspirin and Platelet Count. Possible Dosage Implications

J. Badimón, H. C. Arazi, M. Giorgi, 2012 .

Direct and speciﬁc inhibition of factor Xa: an emerging therapeutic strategy for atherothrombotic disease

J. Badimón, L. Badimón, C. Santos-Gallego, 2014 .

Comparison of Prasugel With Clopidogrel on Platelet Function in Coronary Artery Disease Patients With Type 2 Diabetes Mellitus - Third Optimizing Anti-Platelet Therapy in Diabetes MellitUS (OPTIMUS-3)

J. Badimón, M. Effron, B. Baker, 2009 .

Cocaine As a Possible Emerging Cardiovascular Risk Factor: Response

V. Fuster, J. Badimón, A. Sambola, 2004 .

Anti-thrombotic effect of bivalirudin compared with eptifibatide and unfractionated heparin in diabetic patients

J. Badimón, N. Kleiman, A. Karim, 2006, Thrombosis and Haemostasis.

Not only how much, but also how to, when measuring epicardial adipose tissue.

V. Fuster, J. Badimón, S. Sartori, 2021, Magnetic resonance imaging.

Hirudin reduces tissue factor expression in neointima after balloon injury in rabbit femoral and porcine coronary arteries.

V. Fuster, J. Badimón, J. Fallon, 1998, Circulation.

Up-regulation of reverse cholesterol transport key players and rescue from global inflammation by ApoA-IMilano

V. Fuster, J. Badimón, B. Ibáñez, 2008, Journal of cellular and molecular medicine.

Evolving concepts in the pathogenesis and treatment of arterial thrombosis.

V. Fuster, J. Badimón, J. Fallon, 1995, The Mount Sinai journal of medicine, New York.

Diagnosis of Isolated Noncompaction of the Myocardium by Magnetic Resonance Imaging

V. Fuster, J. Badimón, J. Osende, 2002 .

Images in cardiovascular medicine. Diagnosis of isolated noncompaction of the myocardium by magnetic resonance imaging.

V. Fuster, J. Badimón, J. Osende, 2002, Circulation.

Aspirin Resistance and Atherothrombotic Disease

V. Fuster, J. Badimón, R. Corti, 2006 .

Is Increased Cardiovascular and Bleeding Risk the Price for Pain Relief?: No Free Lunch.

J. Badimón, C. Santos-Gallego, 2020, Journal of the American College of Cardiology.

The Mikamo Lecture 2002. Therapeutic targets for the treatment of atherothrombosis in the new millennium--clinical frontiers in atherosclerosis research.

V. Fuster, J. Badimón, R. Corti, 2002, Circulation journal : official journal of the Japanese Circulation Society.

Increased circulating tissue factor and blood thrombogenicity in Type-2 diabetes

V. Fuster, J. Badimón, Y. Nemerson, 2002 .

Cardiovascular Imaging Spontaneous Echo Contrast Videodensity Is Flow-Related and Is Dependent on the Relative Concentrations of Fibrinogen and Red Blood Cells

V. Fuster, J. Badimón, B. Coller, 2016 .

From vulnerable plaque to vulnerable patient--Part III: Executive summary of the Screening for Heart Attack Prevention and Education (SHAPE) Task Force report.

Yoram Rudy, Morteza Naghavi, John Rumberger, 2006, The American journal of cardiology.

MRI and Characterization of Atherosclerotic Plaque: Emerging Applications and Molecular Imaging

V. Fuster, Z. Fayad, J. Badimón, 2002, Arteriosclerosis, thrombosis, and vascular biology.

Reduced acute vascular injury and atherosclerosis in hyperlipidemic mice transgenic for lysozyme.

J. Badimón, G. Striker, J. Uribarri, 2006, The American journal of pathology.

Effects of Percutaneous Transluminal Angioplasty and Endovascular Brachytherapy on Vascular Remodeling of Human Femoropopliteal Artery by Noninvasive Magnetic Resonance Imaging

Luca Cozzi, Rolf Wyttenbach, Valentin Fuster, 2004, Circulation.

Images in cardiovascular medicine. Effect of percutaneous transluminal angioplasty on severely stenotic femoral lesions: in vivo demonstration by noninvasive magnetic resonance imaging.

V. Fuster, J. Badimón, A. Gallino, 2002, Circulation.

Role of Niacin in Cardiovascular Prevention: The Debate Continues.

J. Badimón, W. Masson, D. Siniawski, 2017, The American journal of medicine.

Coronary artery disease: pathogenesis and acute coronary syndromes.

V. Fuster, J. Badimón, G. Helft, 2001, The Mount Sinai journal of medicine, New York.

High-Density Lipoprotein-Targeted Therapies-Not Dead Yet.

J. Badimón, C. Santos-Gallego, Á. García-Ropero, 2018, JAMA cardiology.

Prolyl Hydroxylase Inhibitors: a New Opportunity in Renal and Myocardial Protection

J. Badimón, M. U. Zafar, J. A. Requena-Ibáñez, 2021, Cardiovascular Drugs and Therapy.

A Novel Nonobstructive Intravascular MRI Coil: In Vivo Imaging of Experimental Atherosclerosis

Meir Shinnar, Zahi A Fayad, Clyde Schechter, 2003, Arteriosclerosis, thrombosis, and vascular biology.

Acute ApoA-I Milano administration induces plaque regression and stabilisation in the long term

V. Fuster, J. Badimón, C. Sirtori, 2012, Thrombosis and Haemostasis.

Letter by Choi et al regarding article, "Effects of the selective estrogen receptor modulator raloxifene on coronary outcomes in the raloxifene use for the heart trial: results of subgroup analyses by age and other factors".

J. Badimón, G. Vilahur, B. Choi, 2009, Circulation.

Update in atherothrombotic disease.

V. Fuster, J. Sanz, J. Badimón, 2004, The Mount Sinai journal of medicine, New York.

Myocardial reperfusion injury.

J. Badimón, B. Ibáñez, G. Cimmino, 2007, The New England journal of medicine.

Title Page / Table of Contents / Preface

F. Sofi, R. Abbate, P. Morange, 2003, Pathophysiology of Haemostasis and Thrombosis.

Characterisation and reproducibility of a human ex vivo model of thrombosis.

D. Newby, J. Badimón, K. Fox, 2010, Thrombosis research.

Thrombus Formation on Atherosclerotic Plaques: Pathogenesis and Clinical Consequences

Valentin Fuster, Zahi Fayad, V. Fuster, 2001, Annals of Internal Medicine.

Acute Coronary Syndromes: Pathophysiology and Preventive Priorities

V. Fuster, Z. Fayad, J. Badimón, 1999, Thrombosis and Haemostasis.

Membrane-associated CD40L and sCD40L in atherothrombotic disease

J. Badimón, J. Marmur, J. Viles‐Gonzalez, 2003, Thrombosis and Haemostasis.

Pathogenesis of Atherosclerosis

V. Fuster, J. Badimón, J. Viles‐Gonzalez, 2006 .

Administration of abciximab to patients receiving tirofiban or eptifibatide: effect on platelet function.

J. Badimón, E. Lev, J. Marmur, 2001, Journal of the American College of Cardiology.

Empagliflozin Ameliorates Adverse Left Ventricular Remodeling in Nondiabetic Heart Failure by Enhancing Myocardial Energetics.

V. Fuster, J. Badimón, R. Hajjar, 2019, Journal of the American College of Cardiology.

Transfer of tissue factor from leukocytes to platelets is mediated by CD15 and tissue factor.

J. Badimón, Y. Nemerson, B. Bohrmann, 2000, Blood.

Pharmacology of thienopyridines: rationale for dual pathway inhibition

J. Badimón, B. Ibáñez, G. Vilahur, 2006 .

Coronary artery disease in aging women: a menopause of endothelial progenitor cells?

V. Fuster, J. Badimón, J. Narula, 2012, The Medical clinics of North America.

The role of high-density lipoprotein cholesterol in the prevention and possible treatment of cardiovascular diseases.

J. Badimón, G. Vilahur, D. Yadegar, 2006, Current molecular medicine.

Platelet Thrombus Formation

V. Fuster, S. Vallabhajosula, J. Badimón, 2005 .

Platelet Interaction to Prosthetic Materials—Role of Von Willebrand Factor in Platelet Interaction to PTFE

J. Badimón, L. Badimón, V. Turitto, 1990, Journal of biomaterials applications.

The development of endotension is associated with increased transmission of pressure and serous components in porous expanded polytetrafluoroethylene stent-grafts: characterization using a canine model.

Martin Prince, Evan J Ryer, Valentin Fuster, 2006, Journal of vascular surgery.

Atherothrombosis and high-risk plaque: part I: evolving concepts.

Zahi A Fayad, Valentin Fuster, Roberto Corti, 2005, Journal of the American College of Cardiology.

Systems Pharmacology of Adverse Event Mitigation by Drug Combinations

Ravi Iyengar, Joseph Goldfarb, Omri Gottesman, 2013, Science Translational Medicine.

Vascular Endothelial Growth Factor Regulates Reendothelialization and Neointima Formation in a Mouse Model of Arterial Injury

V. Fuster, J. Badimón, S. Wiegand, 2004, Circulation.

Factor XI/XIa Inhibition: The Arsenal in Development for a New Therapeutic Target in Cardio- and Cerebrovascular Disease

J. Badimón, G. Escolar, M. U. Zafar, 2022, Journal of cardiovascular development and disease.

Antiplatelet Versus Antithrombins

J. Badimón, L. Badimón, P. Roche, 2005 .

Biologic aspects of vulnerable plaque.

J. Badimón, R. Corti, 2002, Current opinion in cardiology.

Application of phospho-CyTOF to characterize immune activation in patients with sickle cell disease in an ex vivo model of thrombosis.

J. Badimón, Adeeb H. Rahman, L. Aledort, 2017, Journal of immunological methods.

Mortality associated with cardiovascular disease in patients with COVID-19

J. Badimón, J. Núñez, J. González-Juanatey, 2020, REC: CardioClinics.

Thrombin/inflammation paradigms: a closer look at arterial and venous thrombosis.

V. Fuster, J. Badimón, J. Viles‐Gonzalez, 2005, American heart journal.

High-density lipoprotein and cardiovascular risk reduction: promises and realities.

J. Badimón, C. Santos-Gallego, 2012, Revista espanola de cardiologia.

Dronedarone exerts anticoagulant and antiplatelet effects independently of its antiarrhythmic actions.

J. Halperin, J. Badimón, M. U. Zafar, 2017, Atherosclerosis.

Perspectives: Direct and specific inhibition of factor Xa: an emerging therapeutic strategy for atherothrombotic disease

J. Badimón, L. Badimón, C. Santos-Gallego, 2014 .

Beginning to understand high-density lipoproteins.

J. Badimón, R. Rosenson, C. Santos-Gallego, 2014, Endocrinology and metabolism clinics of North America.

Direct Oral Anticoagulants and Coronary Artery Disease: The Debacle of Aspirin Era?

J. Badimón, C. Santos-Gallego, Á. García-Ropero, 2020, Journal of cardiovascular pharmacology.

The vulnerable plaque and acute coronary syndromes.

J. Badimón, M. Farkouh, R. Corti, 2002, The American journal of medicine.

Pathogenesis of the acute coronary syndromes and therapeutic implications

J. Badimón, G. Vilahur, L. Badimón, 2002, Pathophysiology of Haemostasis and Thrombosis.

Clustering of Acute and Subacute Stent Thrombosis Related to the Introduction of Generic Clopidogrel

Samin K. Sharma, J. Badimón, R. Mehran, 2014, Journal of cardiovascular pharmacology and therapeutics.

Magnetic resonance imaging of high-risk plaque

J. Badimón, S. Worthley, 2005 .

The Three Processes Leading to Post PTCA Restenosis: Dependence on the Lesion Substrate

V. Fuster, E. Falk, J. Badimón, 1995, Thrombosis and Haemostasis.

Pathophysiology of Acute Coronary Syndrome

J. Badimón, C. Santos-Gallego, B. Picatoste, 2014, Current Atherosclerosis Reports.

Clinical evidence for anti-inflammatory effects of antiplatelet therapy in patients with atherothrombotic disease

Deepak L. Bhatt, S. Steinhubl, T. Lüscher, 2007, Vascular medicine.

The sum of two evils: pneumonia and myocardial infarction: is platelet activation the missing link?

J. Badimón, C. Santos-Gallego, 2014, Journal of the American College of Cardiology.

Pathophysiology of Vulnerability Caused by Thrombogenic (Vulnerable) Blood

J. Badimón, B. Ibáñez, G. Cimmino, 2011 .

Blood thrombogenicity in type 2 diabetes mellitus patients is associated with glycemic control.

V. Fuster, J. Badimón, J. Fallon, 2001, Journal of the American College of Cardiology.

Anxiety is a better predictor of platelet reactivity in coronary artery disease patients than depression.

Gemma Vilahur, Karina W Davidson, Daichi Shimbo, 2010, European heart journal.

Noninvasive In vivo high-resolution magnetic resonance imaging of atherosclerotic lesions in genetically engineered mice.

E A Fisher, V. Fuster, Z. Fayad, 1998, Circulation.

Non-invasive imaging of atherosclerotic plaque macrophage in a rabbit model with F-18 FDG PET: a histopathological correlation

Cheuk Y. Tang, V. Fuster, M. Buchsbaum, 2006, BMC nuclear medicine.

Peroxisome proliferator-activated receptor ligands in atherosclerosis

V. Fuster, J. Badimón, Brian G. Choi, 2004, Expert opinion on investigational drugs.

[Role of coronary risk factors in blood thrombogenicity and acute coronary syndromes].

V. Fuster, J. Badimón, A. Sambola, 2003, Revista espanola de cardiologia.

Sulindac inhibits neointimal formation after arterial injury in wild-type and apolipoprotein E-deficient mice.

C. Cordon-Cardo, J. Badimón, E. Fisher, 2000, Proceedings of the National Academy of Sciences of the United States of America.

The beneficial effects of HDL-C on atherosclerosis: rationale and clinical results

J. Badimón, C. Santos-Gallego, F. Torres, 2011 .

HDL-cholesterol: is it really good? Differences between apoA-I and HDL.

Borja Ibanez, J. Badimón, B. Ibáñez, 2008, Biochemical pharmacology.

Emerging importance of HDL cholesterol in developing high‐risk coronary plaques in acute coronary syndromes

V. Fuster, J. Badimón, J. Viles‐Gonzalez, 2003, Current opinion in cardiology.

Effect of p27 Deficiency and Rapamycin on Intimal Hyperplasia: In Vivo and In Vitro Studies Using a p27 Knockout Mouse Model

V. Fuster, C. Cordon-Cardo, J. Badimón, 2001, Laboratory Investigation.

Evolving Concepts

V. Fuster, J. Badimón, L. Badimón, 2005 .

Exaggerated serotonin-mediated platelet reactivity as a possible link in depression and acute coronary syndromes.

V. Fuster, J. Badimón, K. Davidson, 2002, The American journal of cardiology.

Safe and Sustained Overexpression of Functional Apolipoprotein A-I/High-density Lipoprotein in Apolipoprotein A-I–null Mice by Muscular Adeno-associated Viral Serotype 8 Vector Gene Transfer

V. Fuster, J. Badimón, C. Giannarelli, 2009, Journal of cardiovascular pharmacology.

Atherothrombosis and high-risk plaque: Part II: approaches by noninvasive computed tomographic/magnetic resonance imaging.

Zahi A Fayad, Valentin Fuster, Roberto Corti, 2005, Journal of the American College of Cardiology.

Anti-inflammatory effects of anti-platelet treatment in atherosclerosis.

J. Badimón, H. C. Arazi, 2012, Current pharmaceutical design.

Benefits and Risks of Simvastatin in Patients with Familial Hypercholesterolaemia

J. Badimón, R. Alonso, P. Mata, 2003, Drug safety.

Atherothrombosis: mechanisms and clinical therapeutic approaches

V. Fuster, J. Badimón, J. Chesebro, 1998, Vascular medicine.

MechanismsofArterial Thrombosis inNonparallel Streamlines: Platelet ThrombiGrowon theApexofStenotic Severely Injured VesselWall Experimental StudyinthePigModel

J. Badimón, L. BadimonandJ, 1989 .

Prolonged thrombin inhibition reduces restenosis after balloon angioplasty in porcine coronary arteries.

V. Fuster, J. Badimón, J. Fallon, 1998, Circulation.

Recombinant apolipoprotein A-I Milano rapidly reverses aortic valve stenosis and decreases leaflet inflammation in an experimental rabbit model.

Mario J. Garcia, V. Fuster, J. Badimón, 2010, European heart journal.

1 PATHOGENESIS OF ATHEROSCLEROSIS

V. Fuster, J. Badimón, A. Fernández-Ortiz, 1999 .

Aspirin and clopidogrel in acute coronary syndromes: therapeutic insights from the CURE study.

Deepak L. Bhatt, V. Fuster, H. Jneid, 2003, Archives of internal medicine.

Increasing high-density lipoprotein as a therapeutic target in atherothrombotic disease.

J. Badimón, B. Ibáñez, 2010, Revista espanola de cardiologia.

Inhibition of intimal thickening after balloon angioplasty in porcine coronary arteries by targeting regulators of the cell cycle.

S Marx, V. Fuster, J. Badimón, 1999, Circulation.

Changes in Vascular Geometry in Atherosclerotic Plaque Rupture and Its Relationship to Thrombosis in Acute Vascular Events

J. Badimón, L. Badimón, 1992 .

Inhibition of tissue factor reduces thrombus formation and intimal hyperplasia after porcine coronary angioplasty.

V. Fuster, J. Badimón, J. Fallon, 2000, Journal of the American College of Cardiology.

Clinical implications of clopidogrel resistance

J. Badimón, B. Ibáñez, A. de Miguel, 2008, Thrombosis and Haemostasis.

Atherothrombosis: a widespread disease with unpredictable and life-threatening consequences.

V. Fuster, J. Badimón, J. Viles‐Gonzalez, 2004, European heart journal.

Administration of abciximab during percutaneous coronary intervention reduces both ex vivo platelet thrombus formation and fibrin deposition: implications for a potential anticoagulant effect of abciximab.

P. Meraj, G. Dangas, J. Badimón, 1998, Arteriosclerosis, thrombosis, and vascular biology.

Understanding the pathophysiology of the arterial wall: which method should we choose? Magnetic resonance imaging

V. Fuster, Z. Fayad, J. Badimón, 2002 .

The role of plaque rupture and thrombosis in coronary artery disease.

J. Badimón, A. Zaman, G. Helft, 2000, Atherosclerosis.

Review article The role of plaque rupture and thrombosis in coronary artery disease

J. Badimón, M. Wiener, 2000 .

Acute coronary syndromes: biology

Zahi A Fayad, Valentin Fuster, V. Fuster, 1999, The Lancet.

Effect of an Eccentric Severe Stenosis on Fibrin(ogen) Deposition on Severely Damaged Vessel Wall in Arterial Thrombosis: Relative Contribution of Fibrin(ogen) and Platelets

V. Fuster, J. Badimón, J. Fallon, 1994, Circulation.

Rapid change in plaque size, composition, and molecular footprint after recombinant apolipoprotein A-I Milano (ETC-216) administration: magnetic resonance imaging study in an experimental model of atherosclerosis.

Gemma Vilahur, Lina Badimon, Borja Ibanez, 2008, Journal of the American College of Cardiology.

therothrombosis and High-Risk Plaque art I : Evolving Concepts

J. Badimón, P. Moreno, R. Corti, 2016 .

Acyl-CoA:Cholesterol Acyltransferase Inhibition Reduces Atherosclerosis in Apolipoprotein E—Deficient Mice

J. Badimón, J. Fallon, E. A. Fisher, 2001, Circulation.

Diagnosis of atherosclerosis by imaging.

Mario J. Garcia, Mario J Garcia, J. Badimón, 2009, The American journal of medicine.

Gender differences in blood thrombogenicity in hyperlipidemic patients and response to pravastatin.

P. Meraj, G. Dangas, J. Badimón, 1999, The American journal of cardiology.

Pravastatin therapy in hyperlipidemia: effects on thrombus formation and the systemic hemostatic profile.

P. Meraj, G. Dangas, J. Badimón, 1999, Journal of the American College of Cardiology.

Experimental Models for the Investigation of High-Density Lipoprotein–Mediated Cholesterol Efflux

J. Badimón, C. Giannarelli, C. Santos-Gallego, 2011, Current atherosclerosis reports.

Lipid Lowering by Simvastatin Induces Regression of Human Atherosclerotic Lesions: Two Years’ Follow-Up by High-Resolution Noninvasive Magnetic Resonance Imaging

V. Fuster, Z. Fayad, J. Badimón, 2002, Circulation.

Real time magnetic resonance guided endomyocardial local delivery

J. Badimón, G. Mizsei, J. Viles‐Gonzalez, 2005, Heart.

Spark That Lights the Fire: Infection Triggers Cardiovascular Events

Juan J. Badimon, J. Badimón, C. Santos-Gallego, 2018, Journal of the American Heart Association.

Value or desirability of hemorheological-hemostatic parameter changes as endpoints in blood lipid-regulating trials

J. Badimón, R. Corti, 2001, Current opinion in lipidology.

Development of a preclinical model of ischemic cardiomyopathy in swine.

J. Badimón, Y. Takewa, R. Hajjar, 2011, American journal of physiology. Heart and circulatory physiology.

cardiomyopathy in swine Development of a preclinical model of ischemic

J. Badimón, Y. Takewa, R. Hajjar, 2011 .

Alterations in Thrombosis and Fibrinolysis in the Metabolic Syndrome

J. Badimón, Brian G. Choi, J. Viles‐Gonzalez, 2005 .

Early Metoprolol Administration Before Coronary Reperfusion Results in Increased Myocardial Salvage: Analysis of Ischemic Myocardium at Risk Using Cardiac Magnetic Resonance

Gemma Vilahur, Mario J. Garcia, Borja Ibanez, 2007, Circulation.

Perspectives: The burden of cardiovascular risk factors and coronary heart disease in Europe and worldwide

Gemma Vilahur, Lina Badimon, Juan J. Badimon, 2014 .

Fenofibrate induces plaque regression in hypercholesterolemic atherosclerotic rabbits: in vivo demonstration by high-resolution MRI.

V. Fuster, J. Badimón, J. Fallon, 2007, Atherosclerosis.

Plaque Neovascularization Is Increased in Ruptured Atherosclerotic Lesions of Human Aorta: Implications for Plaque Vulnerability

Juan J. Badimon, Valentin Fuster, Helena Truszczynska, 2004, Circulation.

Effects of Lipid-Lowering by Simvastatin on Human Atherosclerotic Lesions: A Longitudinal Study by High-Resolution, Noninvasive Magnetic Resonance Imaging

V. Fuster, Z. Fayad, J. Badimón, 2001, Circulation.

Lipoprotein metabolism and vascular biology.

V. Fuster, J. Badimón, P. Moreno, 2007 .

Do the SGLT-2 Inhibitors Offer More than Hypoglycemic Activity?

J. Badimón, C. Santos-Gallego, Eduardo Flores, 2018, Cardiovascular Drugs and Therapy.

The pharmacokinetics and pharmacodynamics of SGLT2 inhibitors for type 2 diabetes mellitus: the latest developments

J. Badimón, C. Santos-Gallego, Á. García-Ropero, 2018, Expert opinion on drug metabolism & toxicology.

Randomized Trial of Empagliflozin in Non-Diabetic Patients with Heart Failure and Reduced Ejection Fraction.

V. Fuster, J. Sanz, J. Badimón, 2020, Journal of the American College of Cardiology.

SGLT2 Inhibitors in Heart Failure: Targeted Metabolomics and Energetic Metabolism.

M. Mayr, J. Badimón, C. Santos-Gallego, 2022, Circulation.

Empagliflozin improves quality of life in nondiabetic HFrEF patients. Sub-analysis of the EMPATROPISM trial.

J. Badimón, J. A. Requena-Ibáñez, C. Santos-Gallego, 2022, Diabetes & metabolic syndrome.

Susceptibility to chronic social stress increases plaque progression, vulnerability and platelet activation

E. Nestler, C. Argmann, J. Badimón, 2017, Thrombosis and Haemostasis.

Catheter-based Renal Denervation as a Treatment for Pulmonary Hypertension: Hope or Hype?

J. Badimón, C. Santos-Gallego, 2015, Revista espanola de cardiologia.

Impaired anti-platelet effect of aspirin, inflammation and platelet turnover in cardiac surgery.

J. Badimón, H. Grancelli, H. C. Arazi, 2010, Interactive cardiovascular and thoracic surgery.

Measures of thrombosis and fibrinolysis.

J. Badimón, B. Ibáñez, G. Vilahur, 2006, Clinics in laboratory medicine.

Atherosclerosis and the vulnerable plaque--imaging: Part II.

V. Fuster, J. Badimón, A. Zaman, 2000, Australian and New Zealand journal of medicine.

In vivo magnetic resonance evaluation of atherosclerotic plaques in the human thoracic aorta: a comparison with transesophageal echocardiography.

V. Fuster, Z. Fayad, J. Aguinaldo, 2000, Circulation.

Spontaneous echo contrast videodensity is flow-related and is dependent on the relative concentrations of fibrinogen and red blood cells.

V. Fuster, J. Badimón, B. Coller, 2003, Journal of the American College of Cardiology.

Progression and Regression of Atherosclerotic Lesions: Monitoring With Serial Noninvasive Magnetic Resonance Imaging

Zahi A Fayad, Valentin Fuster, Roberto Corti, 2002, Circulation.

The diagnostic accuracy of ex vivo MRI for human atherosclerotic plaque characterization.

V. Fuster, Z. Fayad, J. Badimón, 1999, Arteriosclerosis, thrombosis, and vascular biology.

The role of high-density lipoprotein cholesterol in atherothrombosis.

J. Badimón, G. Vilahur, Brian G. Choi, 2006, The Mount Sinai journal of medicine, New York.

Selective estrogen receptor modulation influences atherosclerotic plaque composition in a rabbit menopause model.

V. Fuster, J. Badimón, B. Ibáñez, 2008, Atherosclerosis.

Ezetimibe: one step beyond in the battle against atherosclerosis

J. Badimón, B. Ibáñez, 2006 .

In vivo magnetic resonance imaging of post angioplasty coronary vessell wall lesions in pigs

V. Fuster, Z. Fayad, J. Badimón, 1998 .

Intimal Tissue Factor Activity Is Released from the Arterial Wall after Injury

J. Badimón, J. Fallon, M. Roqué, 2000, Thrombosis and Haemostasis.

Rapamycin inhibits vascular smooth muscle cell migration.

J. Badimón, S. Marx, A. Marks, 1996, The Journal of clinical investigation.

Increased thrombus formation relates to ambient blood glucose and leukocyte count in diabetes mellitus type 2.

V. Fuster, J. Badimón, J. Fallon, 2000, The American journal of cardiology.

Caspase-3 and Tissue Factor Expression in Lipid-Rich Plaque Macrophages: Evidence for Apoptosis as Link Between Inflammation and Atherothrombosis

V. Fuster, B. Lüderitz, J. Badimón, 2004, Circulation.

[Novel imaging techniques for quantifying overall atherosclerotic burden].

J. Badimón, B. Ibáñez, M. Orejas, 2007, Revista espanola de cardiologia.

Cardioprotective Effect of Empagliflozin and Circulating Ketone Bodies During Acute Myocardial Infarction

V. Fuster, J. Badimón, S. Sartori, 2023, Circulation. Cardiovascular imaging.

Contrast-enhanced ultrasound imaging detects intraplaque neovascularization in an experimental model of atherosclerosis.

Francesco Faita, Mario J. Garcia, Elisabetta Bianchini, 2010, JACC. Cardiovascular imaging.

In Vivo 16-Slice, Multidetector-Row Computed Tomography for the Assessment of Experimental Atherosclerosis: Comparison With Magnetic Resonance Imaging and Histopathology

V. Fuster, Z. Fayad, J. Sanz, 2004, Circulation.

Renal and Cardiovascular Metabolic Impact Caused by Ketogenesis of the SGLT2 Inhibitors

J. Badimón, Ariana P. Vargas-Delgado, Estefania Arteaga Herrera, 2023, International journal of molecular sciences.

Effects of electret coating technology on coronary stent thrombogenicity

J. Badimón, G. Escolar, E. Lev, 2021, Platelets.

Effects of percutaneous transluminal angioplasty and endovascular brachytherapy on vascular remodeling of human femoropopliteal artery: 2 years follow-up by noninvasive magnetic resonance imaging.

L Cozzi, J. Badimón, L. Cozzi, 2007, European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery.

Platelets and the vulnerable plaque

J. Badimón, M. Sirol, J. Viles‐Gonzalez, 2007 .

Alternatively Spliced Tissue Factor Promotes Plaque Angiogenesis Through the Activation of Hypoxia-Inducible Factor-1&agr; and Vascular Endothelial Growth Factor Signaling

V. Fuster, Z. Fayad, P. Faries, 2014, Circulation.

Treatment of type II endoleaks with a novel polyurethane thrombogenic foam: induction of endoleak thrombosis and elimination of intra-aneurysmal pressure in the canine model.

V. Fuster, P. Christos, R. Dayal, 2005, Journal of vascular surgery.

Noninvasive in vivo magnetic resonance imaging of experimental coronary artery lesions in a porcine model.

V. Fuster, Z. Fayad, J. Badimón, 2000, Circulation.

Can We Stratify Cardiovascular Risk in Argentina

J. Badimón, C. Santos-Gallego, 2014 .

A canine model to study the significance and hemodynamics of type II endoleaks.

V. Fuster, R. Dayal, P. Faries, 2005, The Journal of surgical research.

Alternatively Spliced Tissue Factor Promotes Plaque Angiogenesis Through the Activation of HIF-1α and VEGF Signaling

V. Fuster, Z. Fayad, P. Faries, 2014 .

Validation study of a semi-automated program for quantification of atherosclerotic burden.

V. Fuster, J. Badimón, B. Ibáñez, 2007, Journal of cardiovascular magnetic resonance : official journal of the Society for Cardiovascular Magnetic Resonance.

Leuko-platelet index predicts thrombotic events in patients with acute coronary syndrome.

J. Badimón, J. Costabel, H. C. Arazi, 2020, International journal of cardiology.

THE SGLT2 INHIBITOR EMPAGLIFLOZIN DOES NOT EXHIBIT PRO THROMBOTIC EFFECTS

V. Fuster, J. Badimón, R. Hajjar, 2018 .

Characterization of retrograde collateral (type II) endoleak using a new canine model.

V. Fuster, R. Dayal, P. Faries, 2004, Journal of vascular surgery.

Overview of Aspirin and Platelet Biology.

J. Badimón, C. Santos-Gallego, 2021, The American journal of cardiology.

Cardiovascular disease prevention and care in Latino and Hispanic subjects.

W. Kannel, H. Rodbard, J. Badimón, 2007, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

Links between inflammation and thrombogenicity in atherosclerosis.

V. Fuster, J. Badimón, J. Viles‐Gonzalez, 2006, Current molecular medicine.

In vivo non-invasive serial monitoring of FDG-PET progression and regression in a rabbit model of atherosclerosis

Cheuk Y. Tang, V. Fuster, M. Buchsbaum, 2009, The International Journal of Cardiovascular Imaging.

In vivo noninvasive detection and age definition of arterial thrombus by MRI.

V. Fuster, Z. Fayad, B. Drayer, 2002, Journal of the American College of Cardiology.

Syndromes of accelerated atherosclerosis: role of vascular injury and smooth muscle cell proliferation.

V. Fuster, J. Badimón, L. Badimón, 1990, Journal of the American College of Cardiology.

Cyclosporine before PCI in Acute Myocardial Infarction.

J. Badimón, C. Santos-Gallego, 2016, The New England journal of medicine.

[Baseline clinical characteristics and management of patients included in IBERICAN study].

J. Badimón, V. Barrios, C. Escobar, 2015, Semergen.

Transfer of tissue factor from leukocytes to platelets is mediated by CD15 and tissue factor.

J. Badimón, Y. Nemerson, B. Bohrmann, 2000, Blood.

Human monocyte-derived macrophages induce collagen breakdown in fibrous caps of atherosclerotic plaques. Potential role of matrix-degrading metalloproteinases and implications for plaque rupture.

V. Fuster, E. Falk, J. Badimón, 1995, Circulation.

Clinical-pathological correlations of coronary disease progression and regression.

V. Fuster, J. Badimón, L. Badimón, 1992, Circulation.

Normalization of platelet reactivity in clopidogrel‐treated subjects

V. Fuster, J. Badimón, G. Vilahur, 2007, Journal of thrombosis and haemostasis : JTH.

Regression of atherosclerotic lesions by high density lipoprotein plasma fraction in the cholesterol-fed rabbit.

V. Fuster, J. Badimón, L. Badimón, 1990, The Journal of clinical investigation.

Negative impact of depression on outcomes in patients with coronary artery disease: mechanisms, treatment considerations, and future directions

V. Fuster, J. Badimón, D. Haas, 2005, Journal of thrombosis and haemostasis : JTH.

Mouse model of femoral artery denudation injury associated with the rapid accumulation of adhesion molecules on the luminal surface and recruitment of neutrophils.

J. Badimón, J. Fallon, M. Roqué, 2000, Arteriosclerosis, thrombosis, and vascular biology.

Echocardiographic "smoke" is produced by an interaction of erythrocytes and plasma proteins modulated by shear forces.

V. Fuster, J. Badimón, M. Cohen, 1992, Journal of the American College of Cardiology.

HDL therapy today: from atherosclerosis, to stent compatibility to heart failure

J. Badimón, C. Sirtori, G. Chiesa, 2019, Annals of medicine.

Role of high density lipoproteins in the regression of atherosclerosis.

V. Fuster, J. Badimón, L. Badimón, 1992, Circulation.

High density lipoprotein plasma fractions inhibit aortic fatty streaks in cholesterol-fed rabbits.

V. Fuster, J. Badimón, L. Badimón, 1989, Laboratory investigation; a journal of technical methods and pathology.

Clinical Benefit of Bempedoic Acid in Randomized Clinical Trials.

J. Badimón, J. Castellano, L. Fácila, 2023, American Journal of Cardiology.

Plaque progression and regression in atherothrombosis

J. Badimón, B. Ibáñez, G. Vilahur, 2007, Journal of thrombosis and haemostasis : JTH.

Rationale and Design of the SOTA-P-CARDIA Trial (ATRU-V): Sotagliflozin in HFpEF Patients Without Diabetes.

J. Sanz, J. Badimón, P. Moreno, 2023, Cardiovascular drugs and therapy.

HDL-induced prostacyclin release in smooth muscle cells is dependent on cyclooxygenase-2 (Cox-2).

J. Badimón, L. Badimón, J. Badimon, 1997, Arteriosclerosis, thrombosis, and vascular biology.

von Willebrand Factor and Cardiovascular Disease

V. Fuster, J. Badimón, L. Badimón, 1993, Thrombosis and Haemostasis.

Ovariectomy increases vascular calcification via the OPG/RANKL cytokine signalling pathway

V. Fuster, J. Badimón, B. Ibáñez, 2008, European journal of clinical investigation.

Mechanisms of arterial thrombosis in nonparallel streamlines: platelet thrombi grow on the apex of stenotic severely injured vessel wall. Experimental study in the pig model.

J. Badimón, L. Badimón, J. Badimon, 1989, The Journal of clinical investigation.

Pravastatin: an antithrombotic effect independent of the cholesterol-lowering effect.

P. Meraj, G. Dangas, J. Badimón, 2000 .

Characterization of the relative thrombogenicity of atherosclerotic plaque components: implications for consequences of plaque rupture.

V. Fuster, J. Badimón, P. Shah, 1994, Journal of the American College of Cardiology.

The efficacy of intensive lipid-lowering therapies on the reduction of LDLc and of major cardiovascular events.

J. Badimón, G. Vilahur, L. Badimón, 2023, Journal of clinical lipidology.

Antithrombotic effect of FK506 vs cyclosporine in cardiac transplant recipients: potential implications in transplant arteriopathy.

V. Fuster, J. Badimón, A. Gass, 1999, The Journal of Heart and Lung Transplantation.

The role of platelets, thrombin and hyperplasia in restenosis after coronary angioplasty.

V. Fuster, J. Badimón, L. Badimón, 1991, Journal of the American College of Cardiology.

Prevention of Thromboembolism Induced by Prosthetic Heart Valves

V. Fuster, J. Badimón, L. Badimón, 1988, Seminars in thrombosis and hemostasis.

Improving Cardiovascular Risk Stratification in Argentina: an Impossible Task or “Impossible is Nothing”?

J. Badimón, C. Santos-Gallego, 2016 .

Integration of vascular biology and magnetic resonance imaging in the understanding of atherothrombosis and acute coronary syndromes

V. Fuster, Z. Fayad, J. Badimón, 2003, Journal of thrombosis and haemostasis : JTH.

Atherothrombosis: mechanisms and clinical therapeutic approaches

V. Fuster, J. Badimón, J. Chesebro, 1998, Vascular medicine.

Lipid lowering therapy reduces blood thrombogenicity in hypercholesterolemic patients: effect of simvastatin

V. Fuster, J. Badimón, J. Fallon, 1998 .

Plaque rupture, thrombosis, and therapeutic implications.

V. Fuster, J. Badimón, J. Fallon, 1996, Haemostasis.

Statins and cardiovascular diseases: the multiple effects of lipid-lowering therapy by statins.

V. Fuster, J. Badimón, J. Fallon, 2000, Atherosclerosis.

Anxiety is a better predictor of platelet reactivity in coronary artery disease patients than depression.

V. Fuster, W. Chaplin, J. Badimón, 2010, European heart journal.

The porcine model for the understanding of thrombogenesis and atherogenesis.

J. Badimón, L. Badimón, J. Chesebro, 1991, Mayo Clinic proceedings.

Inhalation in Man Particle Traps Prevent Adverse Vascular and Prothrombotic Effects of Diesel Engine Exhaust

T. Sandström, J. Badimón, F. Cassee, 2011 .

Genesis and Dynamics of Atherosclerotic Lesions: Implications for Early Detection

J. Badimón, B. Ibáñez, G. Cimmino, 2009, Cerebrovascular Diseases.

Abstract 18200: Intracoronary Delivery of Bioabsorbable Alginate Matrix (IK-5001) Ameliorates Adverse Post-infarction Left Ventricular Remodeling and Improves Left Ventricular Function in a Porcine Model of Reperfused Myocardial Infarction

V. Fuster, J. Badimón, R. Hajjar, 2015 .

Local Delivery of an Ultra-short-acting Nitric Oxide- releasing Compound, DMHD/NO, Is Highly Effective in Inhibiting Acute Platelet-Thrombus Formation on Injured Arterial Strips

S. Kaul, M. Fishbein, T. Naqvi, 1997, Journal of cardiovascular pharmacology and therapeutics.

The Sphingosine 1-Phosphate Receptor Agonist Fingolimod Increases Myocardial Salvage and Decreases Adverse Post-Infarction Left Ventricular Remodeling in a Porcine Model of Ischemia-Reperfusion

V. Fuster, P. Sengupta, J. Badimón, 2016 .

Rationale and Design of the EMPA-TROPISM Trial (ATRU-4): Are the “Cardiac Benefits” of Empagliflozin Independent of its Hypoglycemic Activity?

V. Fuster, J. Sanz, J. Badimón, 2019, Cardiovascular Drugs and Therapy.

Experimental Models for the Investigation of High-Density Lipoprotein–Mediated Cholesterol Efflux

J. Badimón, C. Giannarelli, C. Santos-Gallego, 2011, Current Atherosclerosis Reports.

Do the SGLT-2 Inhibitors Offer More than Hypoglycemic Activity?

J. Badimón, C. Santos-Gallego, Eduardo Flores, 2018, Cardiovascular Drugs and Therapy.

Beginning to understand high-density lipoproteins.

J. Badimón, R. Rosenson, C. Santos-Gallego, 2014, Endocrinology and metabolism clinics of North America.

Different response to balloon angioplasty of carotid and coronary arteries: effects on acute platelet deposition and intimal thickening.

V. Fuster, J. Badimón, J. Fallon, 1998, Atherosclerosis.

Novel Small Leucine-Rich Repeat Protein Podocan Is a Negative Regulator of Migration and Proliferation of Smooth Muscle Cells, Modulates Neointima Formation, and Is Expressed in Human Atheroma

V. Fuster, J. Badimón, C. Giannarelli, 2013, Circulation.

Apoptosis, proliferation, and p27 expression during vessel wall healing: time course study in a mouse model of transluminal femoral artery injury.

V. Fuster, C. Cordon-Cardo, J. Badimón, 2000, Journal of vascular surgery.

Modulatory Role of Pulsatility on von Willebrand Factor Implications for Mechanical Circulatory Support – Associated Bleeding*

J. Badimón, C. Santos-Gallego, 2022 .

Platelet glycoprotein IIb/IIIa receptor antagonists in cardiovascular disease.

V. Fuster, J. Badimón, D. Vorchheimer, 1999, JAMA.

Acute antithrombotic effects of ximelagatran, an oral direct thrombin inhibitor, and r‐hirudin in a human ex vivo model of arterial thrombosis

J. Badimón, J. Osende, U. Eriksson, 2003, Journal of thrombosis and haemostasis : JTH.

831-1 Ruptured diabetic atherosclerotic plaques have more inflammation and neovascularization than ruptured plaques from patients without diabetes

V. Fuster, J. Badimón, P. Moreno, 2004 .

Inhibition of growth of thrombus on fresh mural thrombus. Targeting optimal therapy.

V. Fuster, J. Badimón, L. Badimón, 1994, Circulation.

Dissolution of mural thrombus by specific thrombin inhibition with r-hirudin: comparison with heparin and aspirin.

V. Fuster, J. Badimón, J. Fallon, 1998, Circulation.

Atherothrombosis: A widespread disease with unpredictable and life-threatening consequences

J. Badimón, J. Viles‐Gonzalez, Valentín Fuster, 2004 .

Effects of percutaneous transluminal angioplasty and endovascular brachytherapy on vascular remodeling of human femoropopliteal artery: 2 years follow-up by noninvasive magnetic resonance imaging.

J. Badimón, L. Cozzi, A. Gallino, 2007, European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery.

Effects of Percutaneous Transluminal Angioplasty and Endovascular Brachytherapy on Vascular Remodeling of Human Femoropopliteal Artery by Noninvasive Magnetic Resonance Imaging

V. Fuster, J. Badimón, L. Cozzi, 2004, Circulation.

Thrombosis and accelerated atherosclerosis in coronary bypass surgery and restenosis after percutaneous transluminal coronary angioplasty: implications for therapy

V. Fuster, J. Badimón, L. Badimón, 1990 .

Cod liver oil alters platelet-arterial wall response to injury in pigs.

V. Fuster, J. Badimón, J. Chesebro, 1992, Circulation research.

Men are from Mars but women are not from Venus: The benefits of SGLT2 inhibitors after myocardial infarction are independent of gender.

J. Badimón, C. Santos-Gallego, 2023, Hellenic journal of cardiology : HJC = Hellenike kardiologike epitheorese.

SGLT2-Inhibitors on HFpEF Patients. Role of Ejection Fraction

J. Badimón, M. U. Zafar, J. A. Requena-Ibáñez, 2022, Cardiovascular Drugs and Therapy.

Synergistic action of severe wall injury and shear forces on thrombus formation in arterial stenosis: definition of a thrombotic shear rate threshold.

V. Fuster, J. Badimón, M. Cohen, 1994, Journal of the American College of Cardiology.

Importance of experimental models for the development of clinical trials on thromboatherosclerosis.

J. Badimón, L. Badimón, J. Chesebro, 1991, Circulation.

Ovariectomy increases vascular calcification via the OPG/RANKL cytokine signalling pathway

J. Badimón, G. Vilahur, D. Yadegar, 2008, European journal of clinical investigation.